Crippa Stefano, Domínguez Ismael, Rodríguez J Ruben, Razo Oswaldo, Thayer Sarah P, Ryan David P, Warshaw Andrew L, Fernández-del Castillo Carlos
Wang Ambulatory Care Center 460, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, Boston, MA 02114, USA.
J Gastrointest Surg. 2008 May;12(5):783-93; discussion 793-4. doi: 10.1007/s11605-007-0391-9. Epub 2008 Mar 4.
In pancreatic cancer patients, survival and palliation of symptoms should be balanced with social and functional impairment, and for this reason, health-related quality of life measurements could play an important role in the decision-making process. The aim of this work was to evaluate the quality of life and survival in 92 patients with different stages of pancreatic adenocarcinoma who underwent surgical and/or medical interventions. Patients were evaluated with the Functional Assessment of Cancer Therapy questionnaires at diagnosis and follow-up (3 and 6 months). At diagnosis, 28 patients (30.5%) had localized disease (group 1) and underwent surgical resection, 34 (37%) had locally advanced (group 2), and 30 (32.5%) metastatic disease (Group 3). Improvement in quality of life was found in group 1, while in group 3, it decreased at follow-up (p=0.03). No changes in quality of life in group 2 were found. Chemotherapy/chemoradiation seems not to significantly modify quality of life in groups 2 and 3. Median survival time for the entire cohort was 9.8 months (range, 1-24). One-year survival was 74%, 30%, and 16% for groups 1, 2, and 3 respectively (p=0.001). Pancreatic cancer prognosis is still dismal. In addition to long-term survival benefits, surgery impacts favorably quality of life.
在胰腺癌患者中，生存与症状缓解应与社会和功能损害相平衡，因此，与健康相关的生活质量测量在决策过程中可能发挥重要作用。这项研究的目的是评估92例接受手术和/或药物干预的不同阶段胰腺腺癌患者的生活质量和生存情况。在诊断和随访（3个月和6个月）时，使用癌症治疗功能评估问卷对患者进行评估。诊断时，28例（30.5%）患者为局限性疾病（第1组）并接受了手术切除，34例（37%）为局部晚期（第2组），30例（32.5%）为转移性疾病（第3组）。第1组患者的生活质量有所改善，而第3组患者在随访时生活质量下降（p=0.03）。第2组患者的生活质量未发现变化。化疗/放化疗似乎并未显著改变第2组和第3组患者的生活质量。整个队列的中位生存时间为9.8个月（范围1-24个月）。第1组、第2组和第3组的1年生存率分别为74%、30%和16%（p=0.001）。胰腺癌的预后仍然很差。除了具有长期生存益处外，手术对生活质量有积极影响。
